Table 1.
Patient, Tumor, and Treatment Characteristics.
| Median/N (range/%) | |
|---|---|
| Age at diagnosis, year | 81 (75–91) |
| Gender | |
| Female | 21 (43%) |
| Male | 28 (57%) |
| ECOG PS | |
| 0 | 21 (43%) |
| 1 | 23 (47%) |
| 2 | 5 (10%) |
| Histology | |
| Adenocarcinoma | 49 (100%) |
| Tumor location (on pancreas) | |
| Head/neck | 42 (86%) |
| Body/tail | 7 (14%) |
| Tumor cT stage | |
| 1 | 3 (6%) |
| 2 | 18 (37%) |
| 3 | 4 (8%) |
| 4 | 24 (49%) |
| Tumor cN stage | |
| 0 | 42 (86%) |
| 1 | 6 (12%) |
| 2 | 1 (2%) |
| Resectability | |
| Medically inoperable | 8 (16%) |
| Borderline | 18 (37%) |
| Locally advanced | 23 (47%) |
| Initial CA19-9 Level (U/mL) | 235.8 (3–9204) |
| Neoadjuvant chemotherapy | |
| None | 8 (16%) |
| FOLFIRINOX | 6 (12%) |
| Gemcitabine | 4 (8%) |
| Gemcitabine/paclitaxel | 30 (61%) |
| Gemcitabine/paclitaxel/capecitabine | 1 (2%) |
| Duration, days | 98 (7–244) |
| RT details | |
| Total dose, Gy | 50 (40–50) |
| Number of fractions | 5 |
| BED α/β = 10, Gy | 100 (72–100) |
| BED α/β = 3, Gy | 216.7 (146.7–216.7) |
| EQD210, Gy | 83.3 (60–83.3) |
| EQD23, Gy | 130 (88–130) |
| Elective nodal irradiation | 17 (35%) |
| Post RT resection | |
| None | 40 (82%) |
| Pancreaticoduodenectomy | 8 (16%) |
| Distal pancreatectomy | 1 (2%) |
| Time from RT, days | 72 (48–309) |
| R0 | 9 (100%) |
| 90-day mortality | 0 |
| Adjuvant chemotherapy | 21 (43%) |